Identifying druglike inhibitors of myelin-reactive T cells by phenotypic high-throughput screening of a small-molecule library

Journal of Biomolecular Screening

Volumn 12, Issue 4, 2007, Pages 481-489

  Rossi, Christina ^a   Padmanaban, Deepa ^b   Ni, Jake ^b   Yeh, Li An ^b,c   Glicksman, Marcie A ^b   Waldner, Hanspeter ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

Author keywords

EAE; Multiple sclerosis; Phenotypic high throughput screening; Small molecule inhibitors; T cells

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; MYELIN; RECEPTOR BLOCKING AGENT; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR INHIBITOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL TYPE; CONTROLLED STUDY; HIGH THROUGHPUT SCREENING; INFLAMMATION; MOLECULAR WEIGHT; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PARALYSIS; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; FEMALE; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, TRANSGENIC; MYELIN SHEATH; PEPTIDE LIBRARY; T-LYMPHOCYTES;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 34249913464     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057107301272     Document Type: Article

References (25)

1. Noseworthy JH, Lucchinetti C., Rodriguez M., Weinshenker BG: Multiple sclerosis. N Engl J Med 2000 ; 343: 938-952.
2. Pettinelli CB, McFarlin DE: Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J Immunol 1981 ; 127: 1420-1423.
3. Ando DG, Clayton J., Kono D., Urban JL, Sercarz EE: Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol 1989 ; 124: 132-143.
4. Zamvil SS, Steinman L.: The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990 ; 8: 579-621.
5. Waldner H., Whitters MJ, Sobel RA, Collins M., Kuchroo VK: Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor. Proc Natl Acad Sci U S A 2000 ; 97: 3412-3417.
6. Martin R., Sturzebecher CS, McFarland HF: Immunotherapy of multiple sclerosis: where are we? Where should we go? Nat Immunol 2001 ; 2: 785-788.
7. Neuhaus O., Archelos JJ, Hartung HP: Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci 2003 ; 24: 131-138.
8. Youssef S., Stuve O., Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM,, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002 ; 420: 78-84.
9. Nath N., Giri S., Prasad R., Singh AK, Singh I.: Potential targets of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for multiple sclerosis therapy. J Immunol 2004 ; 172: 1273-1286.
10. Ertl P., Rohde B., Selzer P.: Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 2000 ; 43: 3714-3717.
11. Lipinski CA, Lombardo F., Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001 ; 46: 3-26.
12. Liu Y., Lashuel HA, Choi S., Xing X., Case A., Ni J.,, et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol 2003 ; 10: 837-846.
13. Ahn JS, Musacchio A., Mapelli M., Ni J., Scinto L., Stein R.,, et al. Development of an assay to screen for inhibitors of tau phosphorylation by cdk5. J Biomol Screen 2004 ; 9: 122-131.
14. Bakshi P., Liao YF, Gao J., Ni J., Stein R., Yeh LA,, et al. A high-throughput screen to identify inhibitors of amyloid beta-protein precursor processing. J Biomol Screen 2005 ; 10: 1-12.
15. Case A., Ni J., Yeh LA, Stein RL: Development of a mechanism-based assay for tissue transglutaminase-results of a high-throughput screen and discovery of inhibitors. Anal Biochem 2005 ; 338: 237-244.
16. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J Biomol Screen 1999 ; 4: 67-73.
17. Lundholt BK, Scudder KM, Pagliaro L.: A simple technique for reducing edge effect in cell-based assays. J Biomol Screen 2003 ; 8: 566-570.
18. Frohman EM, Racke MK, Raine CS: Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006 ; 354: 942-955.
19. Cantrell DA, Smith KA: The interleukin-2 T-cell system: a new cell growth model. Science 1984 ; 224: 1312-1316.
20. Bradley LM, Dalton DK, Croft M.: A direct role for IFN-gamma in regulation of Th1 cell development. J Immunol 1996 ; 157: 1350-1358.
21. Banchereau J., Steinman RM: Dendritic cells and the control of immunity. Nature 1998 ; 392: 245-252.
22. Bielekova B., Lincoln A., McFarland H., Martin R.: Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J Immunol 2000 ; 164: 1117-1124.
23. Heystek HC, Thierry AC, Soulard P., Moulon C.: Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int Immunol 2003 ; 15: 827-835.
24. Sommer N., Martin R., McFarland HF, Quigley L., Cannella B., Raine CS,, et al. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J Neuroimmunol 1997 ; 79: 54-61.
25. Virley DJ: Developing therapeutics for the treatment of multiple sclerosis. NeuroRx 2005 ; 2: 638-649.